Michael Szarek

MedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial”.

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

Journal of the American Heart Association(2023)10.1161/jaha.122.029216

N/A

1.1DataRank · unranked

40 citations

Philippe Gabríel Steg, Yann Poulouin, Deepak L. Bhatt, Vera Bittner, Rafael Díaz +10 more

Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

European Journal of Preventive Cardiology(2022)10.1093/eurjpc/zwac107

N/A

0.846DataRank · unranked

15 citations

Jennifer McGinniss, Philippe Gabríel Steg, Deepak L. Bhatt, Vera Bittner, Rafael Díaz +12 more

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial

The Lancet Diabetes & Endocrinology(2025)10.1016/s2213-8587(24)00362-0

N/A

0.700DataRank · unranked

31 citations

Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Silvio E. Inzucchi +17 more

Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial

Journal of the American Heart Association(2025)10.1161/jaha.124.038656

N/A

0.450DataRank · unranked

16 citations

Deepak L. Bhatt, Philippe Gabríel Steg, Michael Miller, Eliot A. Brinton, Richard L. Dunbar +8 more

Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial

The American Journal of Medicine(2022)10.1016/j.amjmed.2022.02.016

N/A

0.401DataRank · unranked

5 citations

Patrícia O. Guimarães, Gregory G. Schwartz, Deepak L. Bhatt, Vera Bittner, Andrzej Budaj +13 more

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis

Critical Care Explorations(2023)10.1097/cce.0000000000000997

N/A

0.104DataRank · unranked

1 citations

Garen Manvelian, Alida Coppi, Amy Damask, Michael Cantor, Manuel A. R. Ferreira +35 more

Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial

Diabetes Care(2025)10.2337/dc24-2110

N/A

0DataRank · unranked

10 citations

Michael Szarek, J. Wouter Jukema, Christa M. Cobbaert, Esther Reijnders, Vera Bittner +9 more

Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events

JACC Heart Failure(2023)10.1016/j.jchf.2023.05.026

N/A

0DataRank · unranked

46 citations

Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Darren K. McGuire +17 more

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

European Heart Journal - Cardiovascular Pharmacotherapy(2024)10.1093/ehjcvp/pvae025

N/A

0DataRank · unranked

24 citations

Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Díaz +82 more

Time to Clinical Benefit with Sotagliflozin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Insights from the SCORED Randomized Trial

European Journal of Heart Failure(2024)10.1002/ejhf.3240

N/A

0DataRank · unranked

4 citations

Deepak L. Bhatt, Michael Szarek, Lawrence A. Leiter, Christopher P. Cannon, Renato D. Lópes +5 more